Literature DB >> 33973839

Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.

Zhichao Feng1, Huiling Li1, Huafei Zhao1, Yi Jiang1, Qin Liu1, Qian Chen1, Wei Wang1, Pengfei Rong1.   

Abstract

Background Macrotrabecular-massive (MTM) subtype and vessels encapsulating tumor clusters (VETC) pattern of hepatocellular carcinoma (HCC) are associated with unfavorable prognosis. Purpose To estimate the potential of preoperative CT in the prediction of MTM subtype and VETC pattern. Materials and Methods Patients who underwent surgical resection or liver transplant and preoperative CT for HCC between January 2015 and June 2018 were retrospectively included in the primary cohort. CT imaging features were evaluated by two radiologists. Predictors associated with the MTM subtype or VETC pattern were determined by using logistic regression analyses and the performance was tested in a validation cohort. Prognostic factors associated with early recurrence after surgical resection were identified by using Cox regression analyses. Results The primary cohort included 170 patients (median age, 55 years; interquartile range, 48-63 years; 152 men). Serum α-fetoprotein level higher than 100 ng/mL (odds ratio [OR], 4.3; 95% CI: 2.1, 9.2; P < .001), intratumor necrosis (OR, 5.2; 95% CI: 2.5, 11.0; P < .001), and intratumor hemorrhage (OR, 5.4; 95% CI: 1.3, 23.3; P = .02) were independent predictors for MTM subtype, whereas tumor size greater than 5 cm (OR, 3.8; 95% CI: 1.7, 8.1; P = .001) and intratumor necrosis (OR, 2.1; 95% CI: 1.0, 4.4; P = .045) were independent predictors for VETC pattern. These features were used for the construction of ANH and SN scores (where A is α-fetoprotein level, N is necrosis, H is hemorrhage, and S is size), respectively, which showed comparable prediction performance in the primary and validation cohorts. Preoperative high ANH and high SN phenotype (hazard ratio, 1.9; 95% CI: 1.2, 3.0; P = .01) was independently associated with early recurrence after surgical resection. Conclusion Preoperative CT features could be used for the characterization of macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern and were of prognostic significance for early recurrence in patients with hepatocellular carcinoma. Online supplemental material is available for this article. See also the editorial by Yoon and Kim in this issue. Published under a CC BY 4.0 license.

Entities:  

Year:  2021        PMID: 33973839     DOI: 10.1148/radiol.2021203614

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

Review 1.  Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?

Authors:  Xiaoming Li; Qiandong Yao; Chen Liu; Jian Wang; Huarong Zhang; Shiguang Li; Ping Cai
Journal:  J Hepatocell Carcinoma       Date:  2022-05-05

2.  Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.

Authors:  Roberto Cannella; Marco Dioguardi Burgio; Aurélie Beaufrère; Loïc Trapani; Valérie Paradis; Christian Hobeika; Francois Cauchy; Mohamed Bouattour; Valérie Vilgrain; Riccardo Sartoris; Maxime Ronot
Journal:  JHEP Rep       Date:  2021-09-30

3.  Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma.

Authors:  Tongjia Chu; Chen Zhao; Jian Zhang; Kehang Duan; Mingyang Li; Tianqi Zhang; Shengnan Lv; Huan Liu; Feng Wei
Journal:  Ann Surg Oncol       Date:  2022-06-26       Impact factor: 4.339

Review 4.  Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge.

Authors:  Anna Sessa; Sébastien Mulé; Raffaele Brustia; Hélène Regnault; Athena Galletto Pregliasco; Rami Rhaiem; Vincent Leroy; Daniele Sommacale; Alain Luciani; Julien Calderaro; Giuliana Amaddeo
Journal:  J Hepatocell Carcinoma       Date:  2022-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.